Summary

Report Overview
The Global Lymph Cancer Testing Market reached US$ 8.5 billion in 2023 and is expected to reach US$ 19.63 billion by 2031, growing at a CAGR of 11.3% during the forecast period 2024-2031.
Lymphoma is a type of blood cancer that affects the immune system. It specifically affects white blood cells called lymphocytes, an important part of the immune system. Lymphoma is also called a cancer of the lymphatic system, or lymphatic cancer. In lymphoma, the development of the lymphocytes becomes very uneven. The lymphocytes don’t work properly and tend to multiply out of control.
There are two main types of lymphoma, Hodgkin lymphoma and non-Hodgkin lymphoma. Both types affect the lymphocytes. Over 14,000 people are diagnosed with lymphoma each year in the UK, making it the most common blood cancer. A common lymphoma symptom is lumps. These are swollen lymph nodes (glands). One may get painless swellings on the neck, collarbone, armpit, groin, or other body parts. Some swollen lymph nodes can press on organs and cause pain in the chest, coughing, breathlessness, or pain in the stomach area.
Market Dynamics: Drivers
Increasing prevalence of lymph cancers
The demand for the global lymph cancer testing market is driven by multiple factors. The rising prevalence of lymph cancers propels the market growth.
For instance, according to an article published by the American Cancer Society in January 2024, non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. It is estimated that about 80,620 people (44,590 males and 36,030 females) will be diagnosed with NHL. This includes both adults and children.
It is estimated that about 20,140 people will die from this cancer (11,780 males and 8,360 females). Overall, the chance that a man will develop NHL in his lifetime is about 1 in 42; for a woman, the risk is about 1 in 52. However, each person’s risk can be affected by several risk factors. NHL can occur at any age. It is one of the more common cancers among children, teens, and young adults. Still, the risk of developing NHL increases throughout life, and more than half of people are 65 or older when they are first diagnosed.
Restraints
Factors such as high cost associated with the testing, lack of healthcare infrastructure, shortage of skilled professionals, and stringent regulatory requirements for the approval of new techniques are expected to hamper the market.
Market Segment Analysis
The global lymph cancer testing market is segmented based on test type, disease type, end-user, and region.
The segment CT scan and PET scan accounted for approximately 43.8% of the global lymph cancer testing market share
The CT scan and PET scan segment is expected to hold the largest market share over the forecast period. In this segment, the technological advancements, and rising funds for private manufacturers for research work would drive this market.
Lymphoma can affect different areas at the same time. Whole-body PET/CT can find sites affected by lymphoma such as the bone marrow, liver, and spleen. It’s the most accurate imaging method for staging and re-staging lymphoma and provides a baseline for subsequent evaluation of therapy response and cancer recurrence. PET stands for positron emission tomography. This can help to give a clearer picture of which areas of the body are affected by lymphoma.
Fluoro-deoxy-glucose (FDG) is the radiotracer most often used in PET scans. The image processing techniques, target delineation methodologies, and PET-guided protocols for biologically guided radiation therapy and PET-adaptive therapy are important factors in this regard. The integration of PET with computed tomography (CT) in PET/CT scans enables precise localization of lesions through the accumulation of F-fluoro-d-glucose. PET exhibits superior reliability in diagnosing lymph node metastases compared to conventional imaging modalities such as computed tomography or MRI, positioning it as a valuable non-invasive diagnostic tool.
Market Geographical Share
North America accounted for approximately 42.1% of the global lymph cancer testing market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of lymph cancer, technological advancements, and growing awareness among people, in this region, help to propel the market.
For instance, in June 2024, Roche launched an in vitro diagnostic assay, Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries that accept the EU CE mark. The Ventana B-cell lymphoma diagnostic assay is designed to qualitatively detect Kappa mRNA and Lambda mRNA. The test detects the presence of B-cell lymphomas and plasma cell neoplasms in formalin-fixed, paraffin-embedded (FFPE) human bone marrow and lymphoid tissue.
The increased sensitivity of the test allows for the assessment of more than 60 subtypes of B-cell lymphoma and plasma cell neoplasms on a single tissue slide. The test can also be performed on small biopsies and formalin-fixed tissue, thereby reducing the need for a fresh tissue sample, which may not be available, especially if lymphoma was not originally suspected.
Moreover, according to the Canadian Cancer Society, it is estimated that 11,700 Canadians will be diagnosed with non-Hodgkin lymphoma. 3,100 Canadians will die from non-Hodgkin lymphoma. 6,600 men will be diagnosed with non-Hodgkin lymphoma and 1,800 will die from it. 5,100 women will be diagnosed with non-Hodgkin lymphoma and 1,300 will die from it.
Market Segmentation
By Test Type
Sentinel lymph node Biopsy
Blood Tests
CT Scan & PET Scan
Others
By Disease Type
Non-Hodgkin lymphoma
Hodgkin lymphoma
By End-User
Hospitals
Diagnostic Centers
Research and Educational Institutions
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global lymph cancer testing market include GE Healthcare, Siemens Healthineer, Abbott Laboratories, Canon Medical Systems, Agilent Technologies, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics, and Bio-Rad Laboratories among others.
Key Developments
In March 2024, SCOR announced the launch of the Vitae Lymphoma Risk Calculator, a new addition to the Group’s biometric risk calculator series that aims to expand protection coverage to people with cancer and other critical diseases.
In November 2023, Roswell Park launched an advanced, high-speed blood cancer test. PanHeme is the test that uses next-generation gene sequencing technology to diagnose blood cancers like leukemia, and lymphoma and identify mutations in hundreds of genes in under 72 hours, a dramatic improvement from the three- to four-week wait time for current molecular testing.
Why Purchase the Report?
To visualize the global lymph cancer testing market segmentation based on test type, disease type, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global lymph cancer testing market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global lymph cancer testing market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by Disease Type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Lymph Cancers
4.1.1.2. Technological Advancements
4.1.1.3. Increasing Awareness among People
4.1.2. RestraintsRestrains
4.1.2.1. High Cost Associated with the Testing
4.1.2.2. Lack of Healthcare Infrastructure
4.1.2.3. Shortage of Skilled Professionals
4.1.2.4. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Test Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Sentinel Lymph Node Biopsy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Blood Tests
6.4. CT Scan and PET Scan
6.5. Others
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Non–Hodgkin Lymphoma*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Hodgkin Lymphoma
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Centers
8.4. Research and Educational Institutions
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. GE Healthcare *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Siemens Healthineers
11.3. Abbott Laboratories
11.4. Canon Medical Systems
11.5. Agilent Technologies
11.6. MDx Health
11.7. Beckman Coulter
11.8. Myriad Genetics
11.9. Ambry genetics
11.10. Bio-Rad Laboratories (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us